| Litigants: | Life Technologies Corp. v. Promega Corp. |
| Arguedate: | December 6 |
| Argueyear: | 2016 |
| Decidedate: | February 22 |
| Decideyear: | 2017 |
| Fullname: | Life Technologies Corporation, et al., Petitioners v. Promega Corporation |
| Usvol: | 580 |
| Uspage: | ___ |
| Parallelcitations: | 137 S. Ct. 734; 197 L. Ed. 2d 33; 121 U.S.P.Q.2d 1641 |
| Docket: | 14–1538 |
| Prior: | Promega Corp. v. Life Techs. Corp., 773 F.3d 1338 (Fed. Cir. 2014); cert. granted, 136 S. Ct. 2505 (2016). |
| Procedural: | On writ of certiorari to the United States Court of Appeals for the Federal Circuit |
| Holding: | The sale of a single component of a patented invention in a foreign market does not give rise to liability under the Patent Act of 1952. |
| Majority: | Sotomayor |
| Joinmajority: | Kennedy, Ginsburg, Breyer, Kagan; Thomas, Alito (all but Part II–C) |
| Concurrence: | Alito (in part) |
| Joinconcurrence: | Thomas |
| Notparticipating: | Roberts |
| Lawsapplied: | Patent Act of 1952, et seq. |
Life Technologies Corp. v. Promega Corp., 580 U.S. ___ (2017), was a case in which the United States Supreme Court clarified the application of the Patent Act of 1952 to the sale of components of patented inventions in foreign markets.[1] In an opinion written by Associate Justice Sonia Sotomayor, the Court held that the sale of a "single component" in a foreign market "does not constitute a substantial portion of the components that can give rise to liability under [the Patent Act of 1952]."[2] Justice Samuel Alito wrote an opinion concurring in part and concurring in the judgment, in which he was joined Justice Clarence Thomas.[3] Chief Justice John Roberts took no part in the decision of the case.[4]